Regulatory

IGI files IND application with US FDA for first-in-class cancer immunotherapy targeting solid tumors

The five-way targeting approach combines three tumour-recognition mechanisms with T-cell and NK-cell activation in a single molecule

  • By IPP Bureau | November 19, 2026
Ichnos Glenmark Innovation (IGI) has taken a major step towards clinical development of its next-generation cancer immunotherapy.
 
The pharma powerhouse has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for ISB 2301, an investigational multispecific therapy targeting solid tumours.
 
Described as a first-in-class pentaspecific immune cell activator, ISB 2301 is designed to recognise three tumour-associated antigens (TAAs) while simultaneously engaging two key components of the immune system: T cells and natural killer (NK) cells.
 
The five-way targeting approach combines three tumour-recognition mechanisms with T-cell and NK-cell activation in a single molecule. IGI aims to use this combination to tackle the biological diversity of solid tumours and overcome features of the tumour microenvironment that suppress immune responses.
 
The company plans to launch a Phase 1 clinical trial evaluating ISB 2301 in patients with solid tumours in 2027.
 
"Submission of the IND for ISB 2301 marks an important milestone in advancing IGI’s multispecific oncology pipeline into clinical development,” said Lida Pacaud, President and Chief Executive Officer, IGI. 
 
“This pentaspecific candidate is designed to integrate multiple tumor-targeting and immune-engaging functions within a single molecule. Our preclinical results have demonstrated a compelling anti-cancer profile for ISB 2301, a candidate we believe to be highly differentiated from current approaches. We plan to initiate a Phase 1 clinical trial of ISB 2301 in patients with solid tumors in 2027.”
 
Developed using IGI’s proprietary BEAT Multispecific Platform, ISB 2301 is engineered to recognise three tumour-associated antigens and activate T cells and NK cells through complementary mechanisms.
 
These include antibody-dependent cellular cytotoxicity (ADCC), checkpoint inhibition and the induction of a sustained type 1 immune response — a combination intended to strengthen immune-mediated attacks against cancer cells.
 
Preclinical studies have also demonstrated favourable pharmacokinetic and tolerability profiles in non-human primates, according to the company. These findings support the planned clinical investigation of the candidate's safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumour activity in patients with advanced solid tumours.
 
The IND submission marks another step in IGI's efforts to expand its multispecific oncology pipeline and bring its BEAT technology platform into clinical development for a broader range of cancers.

Upcoming E-conference

Other Related stories

Startup

Digitization

Collaborative models are practical way to build capability in biologics: Manoj Kumar Panicker, Cytiva and Dr. Sanjib Banerjee, Veeda Lifesciences
Collaborative models are practical way to build capability in biologics: Manoj Kumar Panicker, Cytiva and Dr. Sanjib Banerjee, Veeda Lifesciences
(L-R) Manoj Kumar Panicker, General Manager, South Asia, Cytiva and Dr. Sanjib Banerjee, Chief Operating Officer (Biopharma Services), Veeda Lifesciences.